| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
3 companies
Vlad Coric is Chief Executive Officer at BHVN, with reported holdings spanning 3 companies. Vlad Coric's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $89.2M at current prices.
Our model assigns Vlad Coric a strong insider score of 79/100, based on 9 past trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of +44.1%.
Vlad Coric's largest disclosed position is in MANE as Director, worth about $60.0M. Net of sales, the MANE filings show accumulation of 117,646 shares.
Vlad Coric has 21 Form 4 filings on record from October 2022 to June 2026, across 3 companies: Director at Royalty Pharma (RPRX), 2025–2026; Chief Executive Officer at Biohaven (BHVN), 2022–2026; Director at Veradermics (MANE), 2026.
The 90 reported transactions were 24 other transactions, 21 open-market purchases, 16 option exercises and 12 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 9 purchases worth about $39.5M and no sales.
The largest open-market purchase was 454,545 shares of BHVN at an average $22.00 on October 5, 2023, about $10.0M. Twelve months later BHVN was up 97%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | MANE Veradermics, Incorporated | Director | Buy | 117,646 | $17.00 | $1,999,982.00 | +58.3% | +195.4% | - | |
| Nov 13, 2025 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 666,666 | $7.50 | $4,999,995.00 | +902.4% | +45.8% | - | |
| Oct 2, 2024 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 21,052 | $47.50 | $999,970.00 | +2.5% | -22.2% | -67.7% | |
| Apr 22, 2024 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 121,951 | $41.00 | $4,999,991.00 | +7.3% | -4.9% | -44.8% | |
| Oct 5, 2023 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 454,545 | $22.00 | $9,999,990.00 | +37.8% | +66.4% | +97.2% | |
| Oct 31, 2022 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 25,800 | $15.97 | $411,995.04 | +1.7% | +12.1% | +60.0% | |
| Oct 28, 2022 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 141,930 | $14.84 | $2,105,772.34 | -438.5% | +20.9% | +75.1% | |
| Oct 25, 2022 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 853,380 | $10.50 | $8,960,490.00 | +137.1% | +33.2% | +91.9% | |
| Oct 5, 2022 | BHVN Biohaven Ltd. | Chief Executive Officer | Buy | 485,775 | $10.31 | $5,009,425.05 | -562.7% | +10.2% | +97.1% |